Current Pain and Headache Reports

, Volume 12, Issue 3, pp 201–206 | Cite as

Preventive treatment of migraine: Effect on weight



Weight gain is a common side effect of drugs used for headache prevention. Weight gain can adversely affect patient health, exacerbate comorbid metabolic disorders, and encourage noncompliance. Additionally, obesity may promote the chronification of episodic migraine. Few studies have looked specifically at the effect that headache medications have on weight. The practicing physician needs accurate information about important side effects, including weight gain, when selecting appropriate pharmacologic regimens. This article discusses the potential effects the more common headache medications have on weight.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Bigal ME, Lipton RB: Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 2006, 67:252–257.PubMedCrossRefGoogle Scholar
  2. 2.
    Lipton RB, Stewart WF, Diamond S, et al.: Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001, 41:646–657.PubMedCrossRefGoogle Scholar
  3. 3.
    Silberstein SD, Lipton RB: Chronic daily headache. Curr Opin Neurol 2000, 13:277–283.PubMedCrossRefGoogle Scholar
  4. 4.
    Scher AI, Stewart WF, Ricci JA, et al.: Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003, 106:89.CrossRefGoogle Scholar
  5. 5.
    Mattsson P: Migraine headache and obesity in women aged 40–74 years: a population-based study. Cephalalgia 2007, 27:877–880.PubMedCrossRefGoogle Scholar
  6. 6.
    Tietjen GE, Peterlin BL, Brandes JL, et al.: Depression and anxiety: effect on the migraine-obesity relationship. Headache 2007, 47:866–875.PubMedCrossRefGoogle Scholar
  7. 7.
    Bigal ME, Lipton RB, Holland PR, et al.: Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007, 68:1851–1861.PubMedCrossRefGoogle Scholar
  8. 8.
    Bigal ME, Gironda M, Tepper SJ, et al.: Headache prevention outcome and body mass index. Cephalalgia 2006, 26:445–450.PubMedCrossRefGoogle Scholar
  9. 9.
    Schwartz TL, Nihalani N, Jindal S, et al.: Psychiatric medication-induced obesity: a review. Obes Rev 2004, 5:115–121.PubMedCrossRefGoogle Scholar
  10. 10.
    Pijl H, Meinders AE: Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf 1996, 14:329–342.PubMedCrossRefGoogle Scholar
  11. 11.
    Montgomery SA, Reimitz PE, Zivkov M: Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998, 13:63–73.PubMedGoogle Scholar
  12. 12.
    Hinze-Selch D, Schuld A, Kraus T, et al.: Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000, 23:13–19.PubMedCrossRefGoogle Scholar
  13. 13.
    Mavissakalian MR, Perel JM: The side effects burden of extended imipramine treatment of panic disorder. J Clin Psychopharmacol 2000, 20:547–555.PubMedCrossRefGoogle Scholar
  14. 14.
    Rigler SK, Webb MJ, Redford L, et al.: Weight outcomes among antidepressant users in nursing facilities. J Am Geriatr Soc 2001, 49:49–55.PubMedCrossRefGoogle Scholar
  15. 15.
    Fava M, Judge R, Hoog SL, et al.: Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000, 61:863–867.PubMedGoogle Scholar
  16. 16.
    Young WB, Rozen TD: Preventive treatment of migraine: effect on weight. Cephalalgia 2005, 25:1–11.PubMedCrossRefGoogle Scholar
  17. 17.
    Sachs GS, Guille C: Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999, 60(Suppl 21):16–19.PubMedGoogle Scholar
  18. 18.
    Fabre LF, Abuzzahab FS, Amin M, et al.: Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995, 38:592–602.PubMedCrossRefGoogle Scholar
  19. 19.
    Croft H, Settle E Jr, Houser T, et al.: A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999, 21:643–658.PubMedCrossRefGoogle Scholar
  20. 20.
    Nascimento ED: Prophylaxis of migraine: open study with venlafaxine in 42 patients [in Portuguese]. Arq Neuropsiquiatr 1998, 56:744–746.PubMedGoogle Scholar
  21. 21.
    Amsterdam JD, Garcia-Espana F, Goodman D, et al.: Breast enlargement during chronic antidepressant therapy. J Affect Disord 1997, 46:151–156.PubMedCrossRefGoogle Scholar
  22. 22.
    Wise TN, Perahia DG, Pangallo BA, et al.: Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry 2006, 8:269–278.PubMedGoogle Scholar
  23. 23.
    Leslie WS, Hankey CR, Lean ME: Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007, 100:395–404.PubMedCrossRefGoogle Scholar
  24. 24.
    Ben-Menachem E: Weight issues for people with epilepsy-a review. Epilepsia 2007, 48(Suppl 9):42–45.PubMedCrossRefGoogle Scholar
  25. 25.
    Biton V, Mirza W, Montouris G, et al.: Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001, 56:172–177.PubMedCrossRefGoogle Scholar
  26. 26.
    Privitera MD, Brodie MJ, Mattson RH, et al.: Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003, 107:165–175.PubMedCrossRefGoogle Scholar
  27. 27.
    Isojärvi JIT, Laatikainen TJ, Knip M: Obesity and endocrine disorders in women taking valproate for epilepsy. Arch Neurol 1996, 39:579–584.CrossRefGoogle Scholar
  28. 28.
    Novak GP, Maytal J, Alshansky A, et al.: Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999, 14:490–495.PubMedCrossRefGoogle Scholar
  29. 29.
    Freitag FG, Diamond S, Diamond M, et al.: Divalproex in the long-term treatment of chronic daily headache. Headache 2001, 41:271–278.PubMedCrossRefGoogle Scholar
  30. 30.
    Silberstein SD, Collins SD: Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study (for the Long-Term Safety of Depakote in Headache Prophylaxis Study Group). Headache 1999, 39:633–643.PubMedCrossRefGoogle Scholar
  31. 31.
    Silberstein SD, Freitag FG, Bigal ME: Migraine treatment. In Wolff’s Headache and Other Head Pain, edn 8. Edited by Silberstein SD, Lipton RB, Dodick DW. New York: Oxford University Press; 2008:177–292.Google Scholar
  32. 32.
    Asconape J, Collins T: Weight gain associated with the use of gabapentin [abstract]. Epilepsia 1995, 36:S72.CrossRefGoogle Scholar
  33. 33.
    King JA, Bayles RL: Weight gain during add-on therapy using gabapentin [abstract]. Epilepsia 1995, 36:S72.CrossRefGoogle Scholar
  34. 34.
    deToledo JC, Toledo C, deCerce J, et al.: Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997, 19:394–396.PubMedCrossRefGoogle Scholar
  35. 35.
    Mathew NT, Rapoport A, Saper J, et al.: Efficacy of gabapentin in migraine prophylaxis. Headache 2001, 41:119–128.PubMedCrossRefGoogle Scholar
  36. 36.
    Shorvon SD: Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996, 37(Suppl 2):S18–S22.PubMedCrossRefGoogle Scholar
  37. 37.
    Rosenfeld WE: Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997, 19:1294–1308.PubMedCrossRefGoogle Scholar
  38. 38.
    Smith U, Axelsen M, Hellebo-Johanson E, et al.: Topiramate: a review of preclinical, pharmacokinetic, and clinical data [abstract]. Obes Res 2000, 8:10S.CrossRefGoogle Scholar
  39. 39.
    McElroy SL, Suppes T, Keck PE, et al.: Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000, 47:1025–1033.PubMedCrossRefGoogle Scholar
  40. 40.
    Chengappa R, Levine J, Rathore D, et al.: Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry 2001, 16:186–190.CrossRefGoogle Scholar
  41. 41.
    Edwards KR, Glantz MJ, Norton JA, et al.: Prophylatic treatment of episodic migraine with topiramate: a double-blind, placebo-controlled trial in 30 patients. Cephalalgia 2000, 20:305–322.CrossRefGoogle Scholar
  42. 42.
    Storey JR, Calder CS, Hart DE, et al.: Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001, 41:968–975.PubMedCrossRefGoogle Scholar
  43. 43.
    Bussone G, Diener HC, Pfeil J, et al.: Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005, 59:961–968.PubMedCrossRefGoogle Scholar
  44. 44.
    Faught E, Ayala R, Montouris GG, et al.: Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001, 57:1774–1779.PubMedGoogle Scholar
  45. 45.
    Gadde KM, Franciscy DM, Wagner HR, et al.: Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003, 289:1820–1825.PubMedCrossRefGoogle Scholar
  46. 46.
    Rossner S, Taylor CL, Byington RP, et al.: Long-term propranolol treatment and changes in body weight after myocardial infarction. BMJ 1990, 300:902–903.PubMedCrossRefGoogle Scholar
  47. 47.
    Sharma AM, Pischon T, Hardt S, et al.: Hypothesis: betaadrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001, 37:250–254.PubMedGoogle Scholar
  48. 48.
    Diener HC, Tfelt-Hansen P, Dahlof C, et al.: Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004, 251:943–950.PubMedCrossRefGoogle Scholar
  49. 49.
    Rao BS, Das DG, Taraknath VR, et al.: A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India 2000, 48:223–226.PubMedGoogle Scholar
  50. 50.
    Genazzani AD, Strucchi C, Malavasi B, et al.: Effects of cyproheptadine clorhydrate, a serotonin receptor antagonist, on endocrine parameters in weight-loss related amenorrhea. Gynecol Endocrinol 2001, 15:279–285.PubMedCrossRefGoogle Scholar
  51. 51.
    Morley JE: Anorexia in older persons: epidemiology and optimal treatment. Drugs Aging 1996, 8:134–155.PubMedCrossRefGoogle Scholar
  52. 52.
    Kaplowitz PB, Jennings S: Enhancement of linear growth and weight gain by cyproheptadine in children with hypopituitarism receiving growth hormone therapy. J Pediatr 1987, 110:140–143.PubMedCrossRefGoogle Scholar
  53. 53.
    Maggioni F, Ruffatti S, Dainese F, et al.: Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up. J Headache Pain 2005, 6:322–324.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Jefferson Headache Center, Department of NeurologyThomas Jefferson University HospitalPhiladelphiaUSA

Personalised recommendations